{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:58:38Z","timestamp":1790269118928,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Cellular Molecular Medi"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Induced pluripotent stem cell (iPSC)\u2013derived natural killer (NK) cells offer an opportunity for a standardized, off\u2010the\u2010shelf treatment with the potential to treat a wider population of acute myeloid leukaemia (AML) patients than the current standard of care. FT538 iPSC\u2010NKs express a high\u2010affinity, noncleavable CD16 to maximize antibody dependent cellular cytotoxicity, a CD38 knockout to improve metabolic fitness, and an IL\u201015\/IL\u201015 receptor fusion preventing the need for cytokine administration, the main source of adverse effects in NK cell\u2013based therapies. Here, we sought to evaluate the potential of FT538 iPSC\u2010NKs as a therapy for AML through their effect on AML cell lines and primary AML cells. We observed that FT538 iPSC\u2010NKs induce effector\u2010to\u2010target cell ratio dependent apoptosis in cell lines and primary AML cells, including cells from high\u2010risk patients. Flow cytometric analysis revealed that FT538 iPSC\u2010NKs induce AML cell death when combined with the AML therapies: cytarabine, venetoclax and gilteritinib. Moreover, cytarabine did not affect FT538 iPSC\u2010NK viability, suggesting that iPSC\u2010derived NK therapies and chemotherapy may be a promising treatment combination. This study provides the basis for further study of iPSC\u2010derived NK cell therapies as a treatment option for high\u2010risk AML patients, particularly those with disease resistant to standard therapies.<\/jats:p>","DOI":"10.1111\/jcmm.70169","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T11:55:23Z","timestamp":1736596523000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["<scp>FT538<\/scp>, <scp>iPSC<\/scp>\u2010derived <scp>NK<\/scp> cells, enhance <scp>AML<\/scp> cell killing when combined with chemotherapy"],"prefix":"10.1111","volume":"29","author":[{"given":"Amanda","family":"Eckstrom","sequence":"first","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anudishi","family":"Tyagi","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajid","family":"Mahmood","sequence":"additional","affiliation":[{"name":"Fate Therapeutics, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilly","family":"Wong","sequence":"additional","affiliation":[{"name":"Fate Therapeutics, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Valamehr","sequence":"additional","affiliation":[{"name":"Fate Therapeutics, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1744-4217","authenticated-orcid":false,"given":"Adishwar","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akriti","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5415-9058","authenticated-orcid":false,"given":"V. Lokesh","family":"Battula","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center  Houston Texas USA"},{"name":"Department of Breast Medical Oncology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Acute Myeloid Leukemia","author":"Vakiti A","year":"2024"},{"key":"e_1_2_10_3_1","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics.Surveillance Research Program National Cancer Institute.2023."},{"key":"e_1_2_10_4_1","unstructured":"KolitzJE.Acute myeloid leukemia in adults: Overveiw.2022.https:\/\/www.uptodate.com\/contents\/acute\u2010myeloid\u2010leukemia\u2010in\u2010adults\u2010overview#H1042321829"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2256472"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-551911"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00765-5"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2196482"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.18502\/ijhoscr.v16i1.8443"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01424-6"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31041-9"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.841107"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0801"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw2127"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2021.11.004"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00341-7"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01124"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101073"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2021.08.013"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2014.01.014"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014671"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46343-3"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01541-9"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177527"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.1.346"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22030499"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-17-0550"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.08972"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28497"}],"container-title":["Journal of Cellular and Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jcmm.70169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:47:53Z","timestamp":1746852473000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcmm.70169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/jcmm.70169"],"URL":"https:\/\/doi.org\/10.1111\/jcmm.70169","archive":["Portico"],"relation":{},"ISSN":["1582-1838","1582-4934"],"issn-type":[{"value":"1582-1838","type":"print"},{"value":"1582-4934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70169"}}